Targeting nitrated proteins could lead to new cancer drugs
Glioblastoma multiforme is a type of cancer that develops in the brain. Aggressive and difficult to treat, glioblastoma tumors respond to few drugs, and most patients are treated with methods developed about 20 years ago. Kyle Nguyen, a second-year Ph.D. student in Maria Franco’s laboratory at Oregon State University, has been looking for a new way to target these tumors. He will present his work on Friday, 3–3:15 p.m. EDT, at the 2021 ASBMB Annual Meeting.
In broad terms, the Franco lab is interested in the role of oxidative stress in diseases of the nervous system. Oxidative stress is a chemical imbalance inside cells that leads to an accumulation of oxidants that damage healthy cells. It has been linked to aging and various diseases, including cancer. The lab studies the role of oxidants in the development and growth of tumors of the nervous system.
Peroxynitrite is the most powerful oxidant produced in cancer cells and in cells associated with other diseases. When peroxynitrite reacts with proteins it causes oxidative changes that can negatively affect the way the proteins work in the cells. “As far as we know, these are permanent chemical changes,” Nguyen said.
The lab is interested in tyrosine nitration, one of the changes mediated by peroxynitrite. Tyrosine nitration is virtually undetectable in normal tissues, Nguyen explained, so drugs that target nitrated proteins would not affect healthy cells. His project looked at tyrosine nitration of a protein called heat shock protein 90, or Hsp90. Nitrated Hsp90 promotes the survival of tumor cells, and this role is mediated by nitration of tyrosine residues within this protein.
In his work, Nguyen shows that tyrosine nitration supports the survival and migration of glioblastoma cells and thus is important for tumor development, and that nitrated Hsp90 may play more than one role in these tumors. Non-tumor cells do not have nitrated Hsp90 and tumor cells do, so targeting nitrated Hsp90 or other nitrated proteins could selectively kill tumor cells with few side effects.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Building the blueprint to block HIV
Wesley Sundquist will present his work on the HIV capsid and revolutionary drug, Lenacapavir, at the ASBMB Annual Meeting, March 7–10, in Maryland.
Gut microbes hijack cancer pathway in high-fat diets
Researchers at the Feinstein Institutes for Medical Research found that a high-fat diet increases ammonia-producing bacteria in the gut microbiome of mice, which in turn disrupts TGF-β signaling and promotes colorectal cancer.
Mapping fentanyl’s cellular footprint
Using a new imaging method, researchers at State University of New York at Buffalo traced fentanyl’s effects inside brain immune cells, revealing how the drug alters lipid droplets, pointing to new paths for addiction diagnostics.
Designing life’s building blocks with AI
Tanja Kortemme, a professor at the University of California, San Francisco, will discuss her research using computational biology to engineer proteins at the 2026 ASBMB Annual Meeting.
Cholesterol as a novel biomarker for Fragile X syndrome
Researchers in Quebec identified lower levels of a brain cholesterol metabolite, 24-hydroxycholesterol, in patients with fragile X syndrome, a finding that could provide a simple blood-based biomarker for understanding and managing the condition.
How lipid metabolism shapes sperm development
Researchers at Hokkaido University identify the enzyme behind a key lipid in sperm development. The findings reveal how seminolipids shape sperm formation and may inform future diagnostics and treatments for male infertility.